Compare LMAT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMAT | MESO |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2006 | N/A |
| Metric | LMAT | MESO |
|---|---|---|
| Price | $83.30 | $18.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $101.83 | $24.00 |
| AVG Volume (30 Days) | 177.1K | ★ 224.5K |
| Earning Date | 11-06-2025 | 02-25-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 27.40 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $240,866,000.00 | $17,198,000.00 |
| Revenue This Year | $15.17 | $576.59 |
| Revenue Next Year | $9.07 | $41.15 |
| P/E Ratio | $35.31 | ★ N/A |
| Revenue Growth | 13.07 | ★ 191.39 |
| 52 Week Low | $71.42 | $9.61 |
| 52 Week High | $105.55 | $21.00 |
| Indicator | LMAT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 55.06 |
| Support Level | $79.40 | $17.90 |
| Resistance Level | $86.00 | $18.73 |
| Average True Range (ATR) | 2.22 | 0.52 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 45.64 | 35.48 |
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.